|
||||||
|---|---|---|---|---|---|---|
| Home | 29 CFR | 40 CFR | 49 CFR | Federal Register | MSDS Search | Purchase CFR e-Books |
§799.9537 TSCA in vitro mammalian chromosome aberration test.
(a) Scope -- (1) Applicability. This section is intended to meet testing requirements under section 4 of the Toxic Substances Control Act (TSCA) (15 U.S.C. 2601).
(2) Background. The source material used in developing this TSCA test guideline is the Office of Prevention, Pesticides, and Toxic Substances (OPPTS) harmonized test guideline 870.5375 (August 1998, final guidelines). The source is available at the address in paragraph (i) of this section.
(b) Purpose. (1) The purpose of the in vitro chromosome aberration test is to identify agents that cause structural chromosome aberrations in cultured mammalian cells (see paragraphs (i)(1), (i)(2), and (i)(3) of this section). Structural aberrations may be of two types, chromosome or chromatid. With the majority of chemical mutagens, induced aberrations are of the chromatid type, but chromosome-type aberrations also occur. An increase in polyploidy may indicate that a chemical has the potential to induce numerical aberrations. However, this guideline is not designed to measure numerical aberrations and is not routinely used for that purpose. Chromosome mutations and related events are the cause of many human genetic diseases and there is substantial evidence that chromosome mutations and related events causing alterations in oncogenes and tumour-suppressor genes of somatic cells are involved in cancer induction in humans and experimental animals.
(2) The in vitro chromosome aberration test may employ cultures of established cell lines, cell strains or primary cell cultures. The cells used are selected on the basis of growth ability in culture, stability of the karyotype, chromosome number, chromosome diversity, and spontaneous frequency of chromosome aberrations.
(c) Definitions. The definitions in section 3 of TSCA and in 40 CFR Part 792 -- Good Laboratory Practice Standards apply to this test guideline. The following definitions also apply to this test guideline.
Chromatid-type aberration is structural chromosome damage expressed as breakage of single chromatids or breakage and reunion between chromatids.
Chromosome-type aberration is structural chromosome damage expressed as breakage, or breakage and reunion, of both chromatids at an identical site.
Endoreduplication is a process in which after an S period of DNA replication, the nucleus does not go into mitosis but starts another S period. The result is chromosomes with 4, 8, 16,...chromatids.
Gap is an achromatic lesion smaller than the width of one chromatid, and with minimum misalignment of the chromatid(s).
Mitotic index is the ratio of cells in metaphase divided by the total number of cells observed in a population of cells; an indication of the degree of proliferation of that population.
Numerical aberration is a change in the number of chromosomes from the normal number characteristic of the cells utilized.
Polyploidy is a multiple of the haploid chromosome number (n) other than the diploid number (i.e., 3n, 4n, and so on).
Structural aberration is a change in chromosome structure detectable by microscopic examination of the metaphase stage of cell division, observed as deletions and fragments, intrachanges, and interchanges.
(d) Initial considerations. (1) Tests conducted in vitro generally require the use of an exogenous source of metabolic activation. This metabolic activation system cannot mimic entirely the mammalian in vivo conditions. Care should be taken to avoid conditions which would lead to positive results which do not reflect intrinsic mutagenicity and may arise from changes in pH, osmolality, or high levels of cytotoxicity (the test techniques described in the references under paragraphs (i)(4) and (i)(5) of this section may be used).
(2) This test is used to screen for possible mammalian mutagens and carcinogens. Many compounds that are positive in this test are mammalian carcinogens; however, there is not a perfect correlation between this test and carcinogenicity. Correlation is dependent on chemical class and there is increasing evidence that there are carcinogens that are not detected by this test because they appear to act through mechanisms other than direct DNA damage.
(e) Principle of the test method. Cell cultures are exposed to the test substance both with and without metabolic activation. At predetermined intervals after exposure of cell cultures to the test substance, they are treated with a metaphase-arresting substance (e.g., Colcemid® or colchicine), harvested, stained, and metaphase cells are analysed microscopically for the presence of chromosome aberrations.
(f) Description of the method -- (1) Preparations -- (i) Cells. A variety of cell lines, strains, or primary cell cultures, including human cells, may be used (e.g., Chinese hamster fibroblasts, human, or other mammalian peripheral blood lymphocytes).
(ii) Media and culture conditions. Appropriate culture media, and
incubation conditions (culture vessels, CO (iii) Preparation of cultures -- (A) Established cell lines and
strains. Cells are propagated from stock cultures, seeded in culture medium
at a density such that the cultures will not reach confluency before the time of
harvest, and incubated at 37 °C.
(B) Lymphocytes. Whole blood treated with an anti-coagulant (e.g.,
heparin) or separated lymphocytes obtained from healthy subjects are added to
culture medium containing a mitogen (e.g., phytohemagglutinin) and incubated at
37 °C.
(iv) Metabolic activation. Cells must be exposed to the test substance
both in the presence and absence of an appropriate metabolic activation system.
The most commonly used system is a co-factor-supplemented post-mitochondrial
fraction (S9) prepared from the livers of rodents treated with enzyme-inducing
agents such as Aroclor 1254 (the test techniques described in the references
under paragraphs (i)(6), (i)(7), (8)(i), and (i)(9) of this section may be
used), or a mixture of phenobarbitone and β-naphthoflavone (the test techniques
described in the references under paragraphs (i)(10), (i)(11), and (i)(12) of
this section may be used). The post-mitochondrial fraction is usually used at
concentrations in the range from 1-10% v/v in the final test medium. The
condition of a metabolic activation system may depend upon the class of chemical
being tested. In some cases, it may be appropriate to utilize more than one
concentration of post-mitochondrial fraction. A number of developments,
including the construction of genetically engineered cell lines expressing
specific activating enzymes, may provide the potential for endogenous
activation. The choice of the cell lines used should be scientifically justified
(e.g., by the relevance of the cytochrome P450 isoenzyme for the metabolism of
the test substance).
(v) Test substance/preparation. Solid test substances should be
dissolved or suspended in appropriate solvents or vehicles and diluted, if
appropriate, prior to treatment of the cells. Liquid test substances may be
added directly to the test systems and/or diluted prior to treatment. Fresh
preparations of the test substance should be employed unless stability data
demonstrate the acceptability of storage.
(2) Test conditions -- (i) Solvent/vehicle. The solvent/vehicle
should not be suspected of chemical reaction with the test substance and must be
compatible with the survival of the cells and the S9 activity. If other than
well-known solvent/vehicles are used, their inclusion should be supported by
data indicating their compatibility. It is recommended that wherever possible,
the use of an aqueous solvent/vehicle be considered first. When testing
water-unstable substances, the organic solvents used should be free of water.
Water can be removed by adding a molecular sieve.
(ii) Exposure concentrations. (A) Among the criteria to be considered
when determining the highest concentration are cytotoxicity, solubility in the
test system, and changes in pH or osmolality.
(B) Cytotoxicity should be determined with and without metabolic activation
in the main experiment using an appropriate indication of cell integrity and
growth, such as degree of confluency, viable cell counts, or mitotic index. It
may be useful to determine cytotoxicity and solubility in a preliminary
experiment.
(C) At least three analyzable concentrations should be used. Where
cytotoxicity occurs, these concentrations should cover a range from the maximum
to little or no toxicity; this will usually mean that the concentrations should
be separated by no more than a factor between 2 and √10. At the time of
harvesting, the highest concentration should show a significant reduction in
degree of confluency, cell count or mitotic index, (all greater than 50%). The
mitotic index is only an indirect measure of cytotoxic/cytostatic effects and
depends on the time after treatment. However, the mitotic index is acceptable
for suspension cultures in which other toxicity measurements may be cumbersome
and impractical. Information on cell-cycle kinetics, such as average generation
time (AGT), could be used as supplementary information. AGT, however, is an
overall average that does not always reveal the existence of delayed
subpopulations, and even slight increases in average generation time can be
associated with very substantial delay in the time of optimal yield of
aberrations. For relatively non-cytotoxic compounds the maximum concentration
should be 5 μg/ml, 5mg/ml, or 0.01M, whichever is the lowest.
(D) For relatively insoluble substances that are not toxic at concentrations
lower than the insoluble concentration, the highest dose used should be a
concentration above the limit of solubility in the final culture medium at the
end of the treatment period. In some cases (e.g., when toxicity occurs only at
higher than the lowest insoluble concentration) it is advisable to test at more
than one concentration with visible precipitation. It may be useful to assess
solubility at the beginning and the end of the treatment, as solubility can
change during the course of exposure in the test system due to presence of
cells, S9, serum etc. Insolubility can be detected by using the unaided eye. The
precipitate should not interfere with the scoring.
(iii) Controls. (A) Concurrent positive and negative (solvent or
vehicle) controls both with and without metabolic activation must be included in
each experiment. When metabolic activation is used, the positive control
chemical must be the one that requires activation to give a mutagenic response.
(B) Positive controls must employ a known clastogen at exposure levels
expected to give a reproducible and detectable increase over background which
demonstrates the sensitivity of the test system. Positive control concentrations
should be chosen so that the effects are clear but do not immediately reveal the
identity of the coded slides to the reader. Examples of positive-control
substances include: (C) Other appropriate positive control substances may be used. The use of
chemical class-related positive-control chemicals may be considered, when
available.
(D) Negative controls, consisting of solvent or vehicle alone in the
treatment medium, and treated in the same way as the treatment cultures, must be
included for every harvest time. In addition, untreated controls should also be
used unless there are historical-control data demonstrating that no deleterious
or mutagenic effects are induced by the chosen solvent.
(g) Procedure -- (1) Treatment with test substance. (i)
Proliferating cells are treated with the test substance in the presence and
absence of a metabolic-activation system. Treatment of lymphocytes should
commence at about 48 hours after mitogenic stimulation.
(ii) Duplicate cultures must be used at each concentration, and are strongly
recommended for negative/solvent control cultures. Where minimal variation
between duplicate cultures can be demonstrated (the test techniques described in
the references under paragraphs (i)(13) and (i)(14) of this section may be
used), from historical data, it may be acceptable for single cultures to be used
at each concentration.
(iii) Gaseous or volatile substances should be tested by appropriate methods,
such as in sealed culture vessels (the test techniques described in the
references under paragraphs (i)(15) and (i)(16) of this section may be used).
(2) Culture harvest time. In the first experiment, cells should be
exposed to the test substance both with and without metabolic activation for 3-6
hours, and sampled at a time equivalent to about 1.5 normal cell-cycle length
after the beginning of treatment (the test techniques described in the
references under paragraph (i)(12) of this section may be used). If this
protocol gives negative results both with and without activation, an additional
experiment without activation should be done, with continuous treatment until
sampling at a time equivalent to about 1.5 normal cell-cycle lengths. Certain
chemicals may be more readily detected by treatment/sampling times longer than
1.5 cycle lengths. Negative results with metabolic activation need to be
confirmed on a case-by-case basis. In those cases where confirmation of negative
results is not considered necessary, justification should be provided.
(3) Chromosome preparation. Cell cultures must be treated with
Colcemid® or colchicine usually for 1 to 3 hours prior to harvesting. Each cell
culture must be harvested and processed separately for the preparation of
chromosomes. Chromosome preparation involves hypotonic treatment of the cells,
fixation and staining.
(4) Analysis. (i) All slides, including those of positive and negative
controls, must be independently coded before microscopic analysis. Since
fixation procedures often result in the breakage of a proportion of metaphase
cells with loss of chromosomes, the cells scored must therefore contain a number
of centromeres equal to the modal number ± 2 for all cell types. At least 200
well-spread metaphases should be scored per concentration and control equally
divided amongst the duplicates, if applicable. This number can be reduced when
high numbers of aberrations are observed.
(ii) Though the purpose of the test is to detect structural chromosome
aberrations, it is important to record polyploidy and endoreduplication when
these events are seen.
(h) Data and reporting -- (1) Treatment of results. (i) The
experimental unit is the cell, and therefore the percentage of cells with
structural chromosome aberration(s) should be evaluated. Different types of
structural chromosome aberrations must be listed with their numbers and
frequencies for experimental and control cultures. Gaps are recorded separately
and reported but generally not included in the total aberration frequency.
(ii) Concurrent measures of cytotoxicity for all treated and negative control
cultures in the main aberration experiment(s) should also be recorded.
(iii) Individual culture data should be provided. Additionally, all data
should be summarized in tabular form.
(iv) There is no requirement for verification of a clear positive response.
Equivocal results should be clarified by further testing preferably using
modification of experimental conditions. The need to confirm negative results
has been discussed in paragraph (g)(2) of this section. Modification of study
parameters to extend the range of conditions assessed should be considered in
follow-up experiments. Study parameters that might be modified include the
concentration spacing and the metabolic activation conditions.
(2) Evaluation and interpretation of results. (i) There are several
criteria for determining a positive result, such as a concentration-related
increase or a reproducible increase in the number of cells with chromosome
aberrations. Biological relevance of the results should be considered first.
Statistical methods may be used as an aid in evaluating the test results (see
paragraphs (i)(3) and (i)(13) of this section). Statistical significance should
not be the only determining factor for a positive response.
(ii) An increase in the number of polyploid cells may indicate that the test
substance has the potential to inhibit mitotic processes and to induce numerical
chromosome aberrations. An increase in the number of cells with endoreduplicated
chromosomes may indicate that the test substance has the potential to inhibit
cell-cycle progression (the test techniques described in the references under
paragraphs (i)(17) and (i)(18) of this section may be used).
(iii) A test substance for which the results do not meet the criteria in
paragraphs (h)(2)(i) and (h)(2)(ii) of this section is considered nonmutagenic
in this system.
(iv) Although most experiments will give clearly positive or negative
results, in rare cases the data set will preclude making a definite judgement
about the activity of the test substance. Results may remain equivocal or
questionable regardless of the number of times the experiment is repeated.
(v) Positive results from the in vitro chromosome aberration test
indicate that the test substance induces structural chromosome aberrations in
cultured mammalian somatic cells. Negative results indicate that, under the test
conditions, the test substance does not induce chromosome aberrations in
cultured mammalian somatic cells.
(3) Test report. The test report must include the following
information.
(i) Test substance.
(A) Identification data and CAS no., if known.
(B) Physical nature and purity.
(C) Physicochemical properties relevant to the conduct of the study.
(D) Stability of the test substance, if known.
(ii) Solvent/vehicle.
(A) Justification for choice of solvent/vehicle.
(B) Solubility and stability of the test substance in solvent/vehicle, if
known.
(iii) Cells.
(A) Type and source of cells.
(B) Karyotype features and suitability of the cell type used.
(C) Absence of Mycoplasma, if applicable.
(D) Information on cell-cycle length.
(E) Sex of blood donors, whole blood or separated lymphocytes, mitogen used.
(F) Number of passages, if applicable.
(G) Methods for maintenance of cell cultures if applicable.
(H) Modal number of chromosomes.
(iv) Test conditions.
(A) Identity of metaphase arresting substance, its concentration and duration
of cell exposure.
(B) Rationale for selection of concentrations and number of cultures
including, e.g., cytotoxicity data and solubility limitations, if available.
(C) Composition of media, CO (D) Concentration of test substance.
(E) Volume of vehicle and test substance added.
(F) Incubation temperature.
(G) Incubation time.
(H) Duration of treatment.
(I) Cell density at seeding, if appropriate.
(J) Type and composition of metabolic activation system, including
acceptability criteria.
(K) Positive and negative controls.
(L) Methods of slide preparation.
(M) Criteria for scoring aberrations.
(N) Number of metaphases analyzed.
(O) Methods for the measurements of toxicity.
(P) Criteria for considering studies as positive, negative or equivocal.
(v) Results.
(A) Signs of toxicity, e.g., degree of confluency, cell-cycle data, cell
counts, mitotic index.
(B) Signs of precipitation.
(C) Data on pH and osmolality of the treatment medium, if determined.
(D) Definition for aberrations, including gaps.
(E) Number of cells with chromosome aberrations and type of chromosome
aberrations given separately for each treated and control culture.
(F) Changes in ploidy if seen.
(G) Dose-response relationship, where possible.
(H) Statistical analyses, if any.
(I) Concurrent negative (solvent/vehicle) and positive control data.
(J) Historical negative (solvent/vehicle) and positive control data, with
ranges, means and standard deviations.
(vi) Discussion of the results.
(vii) Conclusion.
(i) References. For additional background information on this test
guideline, the following references should be consulte. These references are
available for inspection at the TSCA Nonconfidential Information Center, Rm.
NE-B607, Environmental Protection Agency, 401 M St., SW., Washington, DC, 12
noon to 4 p.m., Monday through Friday, except legal holidays.
(1) Evans, H.J. Cytological Methods for Detecting Chemical Mutagens. Chemical
Mutagens, Principles and Methods for their Detection, Vol. 4, Hollaender, A. Ed.
Plenum Press, New York and London, pp. 1-29 (1976).
(2) Ishidate, M. Jr. and Sofuni, T. The In Vitro Chromosomal
Aberration Test Using Chinese Hamster Lung (CHL) Fibroblast Cells in Culture.
Progress in Mutation Research, Vol. 5, Ashby, J. et al., Eds. Elsevier Science
Publishers, Amsterdam-New York-Oxford, pp. 427-432 (1985).
(3) Galloway, S.M. et al. Chromosome aberration and sister chromatid
exchanges in Chinese hamster ovary cells: Evaluation of 108 chemicals.
Environmental and Molecular Mutagenesis 10 (suppl. 10), 1-175 (1987).
(4) Scott, D. et al.. Genotoxicity under Extreme Culture Conditions. A report
from ICPEMC Task Group 9. Mutation Research 257, 147-204 (1991).
(5) Morita, T. et al. Clastogenicity of Low pH toVarious Cultured Mammalian
Cells. Mutation Research 268, 297-305 (1992).
(6) Ames, B.N., McCann, J. and Yamasaki, E. Methods for Detecting Carcinogens
and Mutagens with the Salmonella/Mammalian Microsome Mutagenicity Test.
Mutation Research 31, 347-364 (1975).
(7) Maron, D.M. and Ames, B.N. Revised Methods for the Salmonella
Mutagenicity Test. Mutation Research 113, 173-215 (1983).
(8) Natarajan, A.T. et al. Cytogenetic Effects of Mutagens/Carcinogens after
Activation in a Microsomal System In Vitro, I. Induction of Chromosome
Aberrations and Sister Chromatid Exchanges by Diethylnitrosamine (DEN) and
Dimethylnitrosamine (DMN) in CHO Cells in the Presence of Rat-Liver Microsomes.
Mutation Research 37, 83-90 (1976).
(9) Matsuoka, A., Hayashi, M. and Ishidate, M., Jr. Chromosomal Aberration
Tests on 29 Chemicals Combined with S9 Mix In Vitro. Mutation Research
66, 277-290 (1979).
(10) Elliot, B.M. et al. Report of UK Environmental Mutagen Society Working
Party. Alternatives to Aroclor 1254-induced S9 in In Vitro Genotoxicity Assays.
Mutagenesis 7, 175-177 (1992).
(11) Matsushima, T. et al. A Safe Substitute for Polychlorinated Biphenyls as
an Inducer of Metabolic Activation Systems. de Serres, F.J., Fouts, J.R., Bend,
J.R. and Philpot, R.M. Eds. In Vitro Metabolic Activation in Mutagenesis
Testing, Elsevier, North-Holland, pp. 85-88 (1976).
(12) Galloway, S.M. et al. Report from Working Group on In Vitro Tests for
Chromosomal Aberrations. Mutation Research 312, 241-261 (1994).
(13) Richardson, C. et al. Analysis of Data from In Vitro Cytogenetic Assays.
Statistical Evaluation of Mutagenicity Test Data. Kirkland, D.J., Ed. Cambridge
University Press, Cambridge, pp. 141-154 (1989).
(14) Soper, K.A. and Galloway S.M. Replicate Flasks are not Necessary for In
Vitro Chromosome Aberration Assays in CHO Cells. Mutation Research 312,
139-149 (1994).
(15) Krahn, D.F., Barsky, F.C. and McCooey, K.T. CHO/HGPRT Mutation Assay:
Evaluation of Gases and Volatile Liquids. Tice, R.R., Costa, D.L., Schaich, K.M.
Eds. Genotoxic Effects of Airborne Agents. New York, Plenum, pp. 91-103 (1982).
(16) Zamora, P.O. et al. Evaluation of an Exposure System Using Cells Grown
on Collagen Gels for Detecting Highly Volatile Mutagens in the CHO/HGPRT
Mutation Assay. Environmental Mutagenesis 5, 795-801 (1983).
(17) Locke-Huhle, C. Endoreduplication in Chinese hamster cells during
alpha-radiation induced G2 arrest. Mutation Research 119, 403-413 (1983).
(18) Huang, Y., Change, C. and Trosko, J.E. Aphidicolin -- induced
endoreduplication in Chinese hamster cells. Cancer Research 43, 1362-1364
(1983).
[65 FR 78807, Dec. 15, 2000]
------------------------------------------------------------------------
Metabolic activation condition Chemical CAS number
------------------------------------------------------------------------
Absence of exogenous metabolic Methyl [66-27-3]
activation. methanesulfonate.
Ethyl [62-50-0]
methanesulfonate.
Ethylnitrosourea.. [759-73-9]
Mitomycin C....... [50-07-7]
4-Nitroquinoline-N- [56-57-5]
Oxide.
Presence of exogenous metabolic Benzo(a)pyrene.... [50-32-8]
activation.
Cyclophosphamide.. [50-18-0]
(monohydrate)..... ([6055-19-2])
------------------------------------------------------------------------
